Comparison between conventional-dose and high-dose rocuronium use in general anesthesia for Cesarean section.

There have been few studies comparing the effects of high- and low-dose rocuronium during cesarean section by directly measuring the concentration. Therefore, we conducted a study to examine the blood concentrations and clinical effects of both doses of rocuronium on mothers and fetuses. Eighteen patients were randomly assigned to two groups: C Group (0.6 mg/kg), and H Group, (1.0 mg/kg). The primary outcome was the comparison of umbilical vein rocuronium concentration between two groups. We assessed ease of intubation, time from rocuronium administration to some TOF points, post-anesthesia care unit (PACU) stay time, infused remifentanil dose, maternal rocuronium concentration, and Apgar scores. No differences were observed in demographic data, ease of intubation, PACU stay time, 1 min Apgar scores, umbilical venous blood gas analysis between both groups. However, the time from rocuronium administration to T3 disappearance was shorter (=0.009) and time to T1 and T2 reappearance were longer (=0.003, =0.009) in H group than that in C group. The administered remifentanil dose (=0.042) was lower in the H group than in the C group. Rocuronium concentrations in the umbilical vein (=0.004) and maternal vein before cord clamping (=0.002) and at discharge (<0.001) were also found to be higher in the H group than in the C group. We observed no prolongation of PACU stay, and no differences in Apgar scores in H group compared to C group. It suggests that 1.0 mg/kg of rocuronium has no negative effects on the fetus and mother in cesarean section.